0.61%
5.63%
12.36%
13.01%
-7.25%
-12.01%
121.87%
AI Spotlight on WST
Company Description
West Pharmaceutical Services, Inc.designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.It operates in two segments, Proprietary Products and Contract-Manufactured Products.
The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support.This segment serves biologic, generic, and pharmaceutical drug companies.
The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.It serves pharmaceutical, diagnostic, and medical device companies.The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors.
West Pharmaceutical Services, Inc.was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Market Data
| Last Price | 346 |
| Change Percentage | 0.61% |
| Open | 343.11 |
| Previous Close | 343.91 |
| Market Cap ( Millions) | 25058 |
| Volume | 97814 |
| Year High | 413.7 |
| Year Low | 265 |
| M A 50 | 328.82 |
| M A 200 | 322.85 |
Financial Ratios
| FCF Yield | 1.28% |
| Dividend Yield | 0.18% |
| ROE | 18.35% |
| Debt / Equity | 11.08% |
| Net Debt / EBIDTA | -25.02% |
| Price To Book | 9.15 |
| Price Earnings Ratio | 50.42 |
| Price To FCF | 77.92 |
| Price To sales | 8.71 |
| EV / EBITDA | 33.43 |
News
- Jan -30 - West to Host Fourth-Quarter and Full-Year 2024 Conference Call
- Jan -28 - West Announces First-Quarter Dividend
- Jan -22 - West Introduces Daikyo PLASCAP® RUV Closures in New Nested Format at Pharmapack
- Jan -13 - Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth
- Jan -06 - West Pharmaceutical Services to Present at the CJS 25th Annual "New Ideas for the New Year" Investor Conference
- Jan -03 - LH vs. WST: Which Stock Is the Better Value Option?
- Dec -20 - Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
- Dec -11 - West Elects New Director to the Board
- Dec -08 - 3 Dividend Gems You Didn't Know Could Build Lasting Wealth
- Nov -29 - MMSI or WST: Which Is the Better Value Stock Right Now?
- Nov -19 - Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
- Nov -07 - 17 Upcoming Dividend Increases
- Oct -29 - West to Participate in Upcoming Investor Conferences
- Oct -29 - The Zacks Analyst Blog The Gorman-Rupp, Kontoor Brands, Kontoor Brands and Standex International
- Oct -28 - Buy These 4 Stocks With New Dividend Hikes Amid Market Volatility
- Oct -24 - West Pharmaceutical Services, Inc. (WST) Q3 2024 Earnings Call Transcript
- Oct -24 - West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend
- Oct -24 - West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance
- Oct -24 - West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates
- Oct -24 - West Pharmaceutical raises annual profit forecast on demand for medical supplies
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Proprietary Products
Expected Growth : 5 %
What the company do ?
West Pharmaceutical Services, Inc.'s proprietary products include Daikyo Crystal Zenith and NovaPure components, designed for pharmaceutical packaging and delivery systems.
Why we expect these perspectives ?
West Pharmaceutical Services, Inc.'s proprietary products growth is driven by increasing demand for high-value injectable drugs, growing adoption of self-administered injectable devices, and expansion into emerging markets. Additionally, the company's innovative product portfolio, including Daikyo Crystal Zenith and NovaPure components, supports growth through partnerships with leading pharmaceutical companies.
Segment n°2 -> Contract-Manufactured Products
Expected Growth : 7 %
What the company do ?
Contract-Manufactured Products from West Pharmaceutical Services, Inc. offer customized packaging solutions for pharmaceutical and biopharmaceutical companies.
Why we expect these perspectives ?
West Pharmaceutical Services, Inc.'s 7% growth in Contract-Manufactured Products is driven by increasing demand for injectable drugs, rising adoption of prefilled syringes and cartridges, and growing need for pharmaceutical packaging solutions. Additionally, the company's strategic partnerships, capacity expansions, and investments in advanced manufacturing technologies are contributing to its growth momentum.
West Pharmaceutical Services, Inc. Products
| Product Range | What is it ? |
|---|---|
| NovaPure Stopper | A high-quality, ready-to-use stopper designed for use in lyophilization and other pharmaceutical applications |
| FluroTec Stoppers | A line of fluoropolymer-coated stoppers designed for use in pharmaceutical and biotechnology applications |
| Westar RS Stoppers | A line of ready-to-use, sterilized stoppers designed for use in pharmaceutical and biotechnology applications |
| Daikyo Crystal Zenith Stoppers | A line of high-quality, ready-to-use stoppers designed for use in pharmaceutical and biotechnology applications |
| Self-Sealing Stoppers | A line of self-sealing stoppers designed for use in pharmaceutical and biotechnology applications |
| Vial Containment Solutions | A line of vial containment solutions designed for use in pharmaceutical and biotechnology applications |
| Syringe Containment Solutions | A line of syringe containment solutions designed for use in pharmaceutical and biotechnology applications |
| Cartridge Containment Solutions | A line of cartridge containment solutions designed for use in pharmaceutical and biotechnology applications |
| Contract Manufacturing Services | A range of contract manufacturing services designed to support pharmaceutical and biotechnology companies |
| Analytical Services | A range of analytical services designed to support pharmaceutical and biotechnology companies |
West Pharmaceutical Services, Inc.'s Porter Forces
Threat Of Substitutes
West Pharmaceutical Services, Inc. operates in a niche market with high barriers to entry, reducing the threat of substitutes. However, the company's products are not entirely unique, and some customers may find alternative solutions.
Bargaining Power Of Customers
West Pharmaceutical Services, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often critical components of customers' manufacturing processes, making it difficult for customers to negotiate prices.
Bargaining Power Of Suppliers
West Pharmaceutical Services, Inc. relies on a few key suppliers for certain raw materials, which gives these suppliers some bargaining power. However, the company's large scale and diversified supply chain mitigate this risk.
Threat Of New Entrants
The pharmaceutical packaging industry has high barriers to entry, including significant capital expenditures and regulatory hurdles. This makes it difficult for new entrants to compete with established players like West Pharmaceutical Services, Inc.
Intensity Of Rivalry
The pharmaceutical packaging industry is highly competitive, with several established players competing for market share. West Pharmaceutical Services, Inc. must continually innovate and invest in R&D to maintain its market position.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 9.69% |
| Debt Cost | 3.95% |
| Equity Weight | 90.31% |
| Equity Cost | 9.14% |
| WACC | 8.63% |
| Leverage | 10.73% |
West Pharmaceutical Services, Inc. : Quality Control
West Pharmaceutical Services, Inc. passed 9 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| ISRG | Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and … |
| RMD | ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as … |
| ABT | Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. … |
| BDX | Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general … |
| TMO | Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Abbott
A-Score
1-Year Total Return ->
🥈
ResMed
A-Score
1-Year Total Return ->
🥉
Intuitive Surgical
A-Score
1-Year Total Return ->
4
Thermo Fisher
A-Score
1-Year Total Return ->
5
Becton Dickinson
A-Score
1-Year Total Return ->
6
